Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.58
-0.7%		$0.59
$0.47
▼
$2.19
$16.07M1627,080 shs153,785 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.09
-7.6%		$1.92
$1.00
▼
$14.64
$4.21M1.821.20 million shs228,365 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$0.35
-2.7%		$0.39
$0.24
▼
$2.60
$14.68M3.252.23 million shs239,658 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.10
+13.9%		$4.22
$1.11
▼
$17.50
$17.28M0.162,964 shs1,691 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+0.91%-2.77%-18.71%+8.39%-51.63%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-0.84%-7.81%-39.18%-68.11%-91.09%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-2.62%-3.33%-12.61%-5.40%-59.83%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
+15.67%0.00%-16.11%-1.91%-74.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.58
-0.7%		$0.59
$0.47
▼
$2.19
$16.07M1627,080 shs153,785 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.09
-7.6%		$1.92
$1.00
▼
$14.64
$4.21M1.821.20 million shs228,365 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$0.35
-2.7%		$0.39
$0.24
▼
$2.60
$14.68M3.252.23 million shs239,658 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.10
+13.9%		$4.22
$1.11
▼
$17.50
$17.28M0.162,964 shs1,691 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+0.91%-2.77%-18.71%+8.39%-51.63%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-0.84%-7.81%-39.18%-68.11%-91.09%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-2.62%-3.33%-12.61%-5.40%-59.83%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
+15.67%0.00%-16.11%-1.91%-74.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.40
Hold$5.00760.59% Upside
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.00
Hold$13.001,092.66% Upside
Scienture Holdings, Inc. stock logo
SCNX
Scienture
2.00
Hold$1.50331.16% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CVKD, CTXR, SCNX, and ZIVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/19/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$7.11M2.24N/AN/A$4.29 per share0.14
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$430K33.22N/AN/A$1.73 per share0.20
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,090.32N/AN/A($0.81) per share-5.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$37.43M-$1.67N/AN/AN/AN/A-59.57%-34.47%N/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$13.24M-$4.90N/AN/AN/AN/A-406.41%-273.80%11/9/2026 (Estimated)
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$41.51M-$2.10N/AN/AN/AN/A-53.51%-42.47%11/12/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.40N/AN/AN/AN/AN/A-2,240.92%N/A

Latest CVKD, CTXR, SCNX, and ZIVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$0.36-$0.34+$0.02-$0.34$5.46 millionN/A
8/13/2026Q2 2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.42-$1.14+$0.28-$1.14N/AN/A
8/13/2026Q2 2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$0.09-$0.07+$0.02-$0.07$1.96 million$0.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
0.08
0.84
0.40
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
3.73
3.73
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.15
3.04
2.97
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
5.68%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
4.99%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
14.59%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
21.39%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2027.45 million26.08 millionOptionable
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
43.57 million3.05 millionNot Optionable
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/A41.06 million32.28 millionN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Below Two Hundred Day Moving Average - Here's What Happened
September 11 at 2:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016094
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023
March 18, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/?utm_source=marketbeat&utm_medium=referral
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$0.58 0.00 (-0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$0.58 +0.00 (+0.69%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$1.09 -0.09 (-7.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 -0.01 (-0.92%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Scienture stock logo

Scienture NASDAQ:SCNX

$0.35 -0.01 (-2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 0.00 (-0.26%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$4.10 +0.50 (+13.89%)
As of 01:56 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas